Imagine a Google Glass type eyewear that can recognize integrated augmented reality with your own and give you the live information about your surroundings. A new device developed by researchers may make this possible.
They have developed the Google-Glass diagnosis system based on Virtual-Reality (VR) technology to detect early neurodegenerative disorders which also includes Multiple Sclerosis (MS) and Parkinson’s disease. It consists of non-contact sensor controller and a mobile platform.
The motion sensor detects the changes in the human body posture when the person puts on the glasses and selects the VR mode where the environment changes the slope. This system is developed by the Tomsk Polytechnic University (TPU) and Siberian State Medical University (SSMU) in Russia.
According to the researchers, a person without any disorder quickly adapts to VR and keeps a stable position while a person with disease can’t adapt and loses the balance. They have been already tested this system by about 50 volunteers
“We have integrated existing devices and developed mathematical models for data analysis. We have also created a human skeleton model, identified 20 important points that Kinect monitors. Diagnosis provides results of deviations in the 20 points,” said David Khachaturyan, a scientist from TPU.
“In the experiment, we tested how VR influences people. The procedure took almost 10 minutes. The experiment engaged both healthy people and those whom doctors had already been found disorders by,” said Ivan Tolmachov from TPU.
“We have also found out how people with different diseases react to a virtual environment. For instance, people with Parkinson’s disease get hand tremor, more pronounced in the case of a central nervous system,” he said.
According to the reports of researchers, the Parkinson’s disease cell death process will start at the age of 30, but the symptoms will be noticeable at the age of 50. To avoid this type of situation, the scientists had developed the early detectable diagnosis methods for a Neurodegenerative disease.
The researchers had mentioned that the system needs clinical trials and also requires technical and toxicological certification. The system process will be completed in the year 2017.